Conference Day One

Tuesday 30th January, 2024

8:00 am Conference Registration & Morning Coffee

Reimagining Allogeneic Therapies to Mitigate Immune Response & Alloreactivity

8:50 am Chair’s Opening Remarks

9:00 am Industry Leaders’ Fireside Chat: Highlights & Hurdles from the Past Year


• A panel discussion with the C-level leaders who are innovating in the allogeneic cell

therapy field

• Highlighting and celebrating the big wins for allogeneic therapies in the last year

• Considering the challenges facing allogeneic research and the strategy required to

overcome them

9:30 am Exploring the Use of Genome Editing, Cell Armouring, & Other Approaches to Mitigate Immunogenicity


• Utilising CRISPR technologies to reduce immunogenicity of allogeneic CAR-T therapies

• Combatting T-cell exhaustion to create a sustained and hyper-active antitumoural


• Assessing shielding technologies to protect allogeneic cells from immune surveillance

10:00 am Considering Stealth Approaches for Allogeneic Therapies to Avoid Immune System Detection

  • Tim Allsopp Chief Technology Officer, Laverock Therapeutics


• Exploring use of siRNA, shRNA, and microRNA to silence immunogenic signalling in

allogeneic T-cells

• Understanding the benefits awarded to patients by optimising

• Potency vs stealth: evaluating prioritisation of therapy characteristic dependent on

disease type and severity

10:30 am Speed Networking & Morning Refreshments

Predicting Responders & Building Better Banks: Innovations in Donor Selection & Patient Stratification

11:30 am Developing & Validating Biomarkers to Optimise Donor Selection & Patient Stratification

  • Dan Crowley Chief Executive Officer, Remedy Biologics


• Identifying and validating biomarkers to predict donor cell potency and persistence

• Stratifying patients based on predictive biomarkers of therapy response and


• Investigating the biological differences between patient and disease types

12:00 pm Engineering Gamma Delta T cells to Supercharge Cytotoxic Function, Persistence, and Safety


  • Leucid Bio's γδ [T2] Cell Platform: Enhances γδ T cell fitness through optimized serum-free cultivation of Vγ9/Vδ2+ T cells using TGF-β1 and IL-2
  • Enhanced γδ [T2] Cell Efficacy: Cancer cell sensitization using amino bisphosphonates or Ara-C further enhances the efficacy of γδ [T2] cells
  • Advanced performance through IL-18 armouring: Integrating IL-18 into a tailored pCAR significantly boosts cytotoxic function and persistence of γδ [T2] cells
  • Enhanced potency against aggressive tumors: IL-18 armorimg and NKG2D ligand-targeted adaptor CAR empowers γδ [T2] cells against aggressive against solid tumours

12:30 pm Lunch Refreshments & Networking

Improving Persistence Without Compromising Safety: Novel Approaches to Improve Allogeneic Durability

1:30 pm Comparing Knockout Vs Modulation Approaches to Prevent T- & NK-Cell Targeting of Allogeneic Cells


• Reviewing benefits and risks of permanent knockout vs transient modulation of immune


• Strategising how to balance preventing host rejection while maintaining necessary cell


• Assessing engineering strategies that offer optimal control over immune evasion timing

and degree

2:00 pm Harnessing Invariant NKT Cells as a Novel Therapeutic Platform for Blood Cancers


• Evaluating the superior anti-tumour potency of engineered iNKT cells vs T-cells against

B-cell lymphoma

• Developing iNKT cell immunotherapies targeting novel antigens beyond CD19 for

multiple myeloma

• Assessing opportunities and challenges in clinically translating engineered iNKT cell


2:30 pm Afternoon Refreshments & Poster Session

3:30 pm Leveraging Omics Approaches to Identify and Select Highly Potent NK Cell Products

  • Monica Raimo Senior Manager - Research & Development, Glycostem Therapeutics


  • Uncovering the source of heterogeneity in NK cells using transcriptomics and proteomics approaches
  • Identifying the biological differences of superior effectors, to produce more effective therapies
  • Applying signatures of superior donors to product development, with the future goal of identifying them as early as the stem cell stage

4:00 pm Safety Data & Clinical Applications of ProTcell: A Novel, Thymus-Powered T-Cell Therapy Platform


  • Overview of preclinical safety profile of ProTcells (SMART101) in mice models
  • Evaluating diverse clinical applications enabled by rapid in-thymus maturation of ProTcells
  • Highlighting ongoing research developing ProTcells engineered with smart CAR-T cell constructs

4:30 pm Chair’s Closing Remarks

4:45 pm Close of Day 1